CODEN [USA]: IAJPBB ISSN : 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES
SJIF Impact Factor: 7.187
https://doi.org/10.5281/zenodo.18891373

Available online at: http://www.iajps.com Review Article

RECENT ADVANCES IN PHARMACOLOGICAL APPROACHES FOR THE MANAGEMENT OF DIABETES MELLITUS: MECHANISM, THERAPY AND FUTURE PERSPECTIVE

Pranav Rajendra Kadam[1], Sachin Tukaram Kolekar[2], Sumit Santosh Koli[3], Aarti Baliram Bansode[4], Dr. Rahul Ishwara Jadhav[5]
DMKG college of pharmacy, Mangalwedha

Abstract:
Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia resulting from impaired insulin secretion, insulin action, or both. The global prevalence of diabetes has increased dramatically in recent decades, making it one of the most significant public health challenges worldwide. Pharmacological management plays a crucial role in controlling blood glucose levels and preventing complications associated with the disease. Traditional antidiabetic drugs such as insulin, sulfonylureas, and biguanides have been widely used for decades. However, recent advances in pharmacotherapy have introduced several novel classes of drugs including DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and dual agonists targeting multiple metabolic pathways. These therapies offer improved glycemic control with reduced risk of hypoglycemia and additional cardiovascular benefits. This review highlights the pathophysiology of diabetes mellitus, mechanisms of action of various pharmacological agents, recent advancements in antidiabetic drug therapy, and future perspectives for improved management of the disease.

Keywords: *Diabetes mellitus, antidiabetic drugs, insulin resistance, SGLT2 inhibitors, GLP-1 agonists, pharmacotherapy.*

Corresponding author:
Aarti baliram bansode
aaratibandode1211999@gmail.com
DMKG college of pharmacy,Mangalwedha

QR CODE

Please cite this article in press Aarti baliram bansode et al., Recent Advances In Pharmacological Approaches For The Management Of Diabetes Mellitus: Mechanism, Therapy And Future Perspective., Indo Am. J. P. Sci, 2026; 13(03).



Caption: Graphical representation of pharmacological approaches for diabetes management including insulin therapy, metformin, DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors.

1. INTRODUCTION:

Diabetes mellitus is a metabolic disorder characterized by elevated blood glucose levels due to defects in insulin secretion, insulin action, or both. The condition is associated with disturbances in carbohydrate, fat, and protein metabolism. Over time, uncontrolled diabetes can lead to severe complications including cardiovascular disease, neuropathy, nephropathy, and retinopathy.

The two major forms of diabetes are **Type 1 diabetes mellitus**, which results from autoimmune destruction of pancreatic β-cells, and **Type 2 diabetes mellitus**, which is primarily caused by insulin resistance and relative insulin deficiency. Type 2 diabetes accounts for approximately 90–95% of all diabetes cases worldwide.

Lifestyle modifications such as diet control, weight management, and physical activity play an important role in diabetes management. However, pharmacological therapy remains essential for achieving adequate glycemic control in many patients.

In recent years, significant advances have been made in understanding the molecular mechanisms underlying diabetes. These discoveries have led to the development of several innovative pharmacological therapies targeting different metabolic pathways.

Table 1. Classification of Diabetes Mellitus

Type of Diabetes	Description	Key Features
Type 1 Diabetes Mellitus	Autoimmune destruction of pancreatic β-cells leading to insulin deficiency	Requires lifelong insulin therapy
Type 2 Diabetes Mellitus	Characterized by insulin resistance and relative insulin deficiency	Most common form; associated with obesity and lifestyle factors
Gestational Diabetes Mellitus	Glucose intolerance first recognized during pregnancy	Usually resolves after childbirth
Secondary Diabetes	Caused by other diseases or medications	Associated with pancreatic disorders or steroid therapy

Caption:
Classification of diabetes mellitus based on etiology and clinical characteristics.

Table 2. Major Pathophysiological Mechanisms in Diabetes Mellitus

Mechanism	Description	Effect on Glucose Metabolism
Insulin Resistance	Reduced cellular response to insulin	Decreased glucose uptake by tissues
Beta-cell Dysfunction	Impaired insulin secretion from pancreatic β-cells	Elevated blood glucose levels
Increased Hepatic Glucose Production	Excess gluconeogenesis in the liver	Hyperglycemia
Incretin Deficiency	Reduced GLP-1 hormone activity	Impaired insulin secretion
Renal Glucose Reabsorption	Increased glucose reabsorption by kidneys	Elevated blood glucose

Caption:
Key mechanisms contributing to the development of diabetes mellitus.

2. Pathophysiology of Diabetes Mellitus

2.1 Insulin Resistance

Insulin resistance is one of the primary mechanisms responsible for Type 2 diabetes mellitus. In this condition, peripheral tissues such as skeletal muscle, liver, and adipose tissue become less responsive to insulin. As a result, glucose uptake by cells decreases while hepatic glucose production increases, leading to hyperglycemia.

2.2 Beta Cell Dysfunction

Pancreatic β-cells play a vital role in maintaining glucose homeostasis by secreting insulin. In diabetes mellitus, these cells become dysfunctional and gradually lose their ability to produce adequate insulin.

2.3 Increased Hepatic Glucose Production

The liver contributes to hyperglycemia by increasing gluconeogenesis and glycogenolysis. Excess glucose production by the liver further worsens blood glucose levels.

Mechanism of Diabetes Mellitus



Figure 3: Pathophysiology of hyperglycaemia and increased circulating fatty acids in type 2 diabetes

Caption: Major mechanisms involved in diabetes mellitus including insulin resistance, pancreatic β-cell dysfunction, and increased hepatic glucose production.

3. Conventional Pharmacological Therapy

3.1 Insulin Therapy

Insulin therapy is essential for patients with Type 1 diabetes and many individuals with advanced Type 2 diabetes. Various insulin formulations are available including rapid-acting, short-acting, intermediate-acting, and long-acting insulin.

3.2 Metformin

Metformin is the first-line drug for Type 2 diabetes mellitus. It reduces hepatic glucose production and improves insulin sensitivity. Metformin also has beneficial effects on body weight and cardiovascular risk.

3.3 Sulfonylureas

Sulfonylureas stimulate insulin secretion from pancreatic β-cells. Common drugs in this class include glibenclamide, glipizide, and glimepiride.

3.4 Thiazolidinediones

These drugs improve insulin sensitivity in peripheral tissues by activating the PPAR-γ receptor.

Example:

- Pioglitazone

Table 3. Conventional Antidiabetic Drugs

Drug Class	Example Drugs	Mechanism of Action	Therapeutic Role
Biguanides	Metformin	Decreases hepatic glucose production	First-line therapy for type 2 diabetes
Sulfonylureas	Glibenclamide, Glipizide	Stimulate insulin secretion	Improve glycemic control
Thiazolidinediones	Pioglitazone	Increase insulin sensitivity	Used in insulin resistance
Insulin	Rapid, short, long-acting insulin	Replaces endogenous insulin	Essential in type 1 diabetes

Caption:
Commonly used conventional pharmacological therapies for diabetes management.

4. Recent Advances in Antidiabetic Pharmacotherapy

4.1 DPP-4 inhibitors

Dipeptidyl peptidase-4 inhibitors increase the levels of incretin hormones such as GLP-1. These hormones stimulate insulin secretion and suppress glucagon release.

Examples include:

- Sitagliptin
- Saxagliptin
- Linagliptin

4.2 GLP-1 receptor agonists

GLP-1 receptor agonists mimic the action of incretin hormones. They stimulate insulin secretion, reduce glucagon levels, slow gastric emptying, and promote weight loss.

Examples include:

- Liraglutide
- Exenatide
- Semaglutid

4.3 SGLT2 inhibitors

Sodium-glucose cotransporter-2 inhibitors reduce blood glucose levels by increasing urinary glucose excretion through the kidneys.

Examples include:

- Dapagliflozin
- Empagliflozin
- Canagliflozin

These drugs also provide cardiovascular and renal protection.

Table 4. Recent Advances in Antidiabetic Pharmacotherapy

Drug Class	Example	Mechanism of Action	Additional Benefits
DPP-4 Inhibitors	Sitagliptin	Increase incretin hormone levels	Improved insulin secretion
GLP-1 Receptor Agonists	Liraglutide	Mimic incretin hormones	Weight reduction
SGLT2 Inhibitors	Dapagliflozin	Increase urinary glucose excretion	Cardiovascular protection
Dual Incretin Agonists	Tirzepatide	Activates GLP-1 and GIP receptors	Improved glycemic control

Caption:
Recent pharmacological advancements in diabetes therapy.

5. Emerging Therapies

5.1 Dual Incretin Receptor Agonists

Recent studies have explored dual agonists targeting both **GLP-1 and GIP receptors**, which provide improved glycemic control and weight reduction.
Example:

- Tirzepatide

5.2 Gene Therapy

Gene therapy aims to modify genes responsible for insulin production and glucose metabolism. This approach may offer long-term therapeutic benefits.

5.3 Stem Cell Therapy

Stem cell therapy has shown potential for regenerating pancreatic β-cells and restoring insulin production.

5.4 Nanotechnology-Based Drug Delivery

Nanoparticles are being developed to improve drug delivery and enhance bioavailability of antidiabetic drugs.

Table 5. Advantages and Limitations of Modern Antidiabetic Therapies

Therapy	Advantages	Limitations
GLP-1 receptor agonists	Weight loss and improved glucose control	Injectable administration
SGLT2 inhibitors	Cardiovascular and renal benefits	Risk of urinary infections
DPP-4 inhibitors	Low risk of hypoglycemia	Moderate efficacy
Insulin therapy	Strong glucose-lowering effect	Risk of hypoglycemia

Caption:
Comparison of benefits and limitations of modern antidiabetic therapies.

6. Future Perspectives

The future of diabetes treatment lies in developing therapies that target the underlying causes of the disease rather than only controlling symptoms. Advances in molecular biology, pharmacology, and biotechnology are expected to lead to innovative treatments.
Personalized medicine approaches may allow healthcare professionals to select the most effective treatment based on a patient's genetic and metabolic profile. Additionally, combination therapies targeting multiple metabolic pathways may provide improved glycemic control with fewer side effects.

Table 6. Emerging Future Therapies for Diabetes Mellitus

Emerging Therapy	Mechanism	Potential Benefits
Gene Therapy	Corrects defective insulin production genes	Long-term disease management
Stem Cell Therapy	Regeneration of pancreatic β-cells	Restoration of insulin secretion
Nanotechnology Drug Delivery	Targeted drug delivery systems	Improved drug bioavailability
Artificial Pancreas Systems	Automated insulin delivery devices	Improved glucose regulation

Caption:
Future therapeutic strategies under investigation for diabetes treatment.

7. CONCLUSION:

Diabetes mellitus continues to be a major global health challenge due to its increasing prevalence and associated complications. Pharmacological therapy remains a cornerstone in the management of this disease. Conventional drugs such as insulin and metformin have been widely used for decades, while newer classes of drugs including DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors offer improved therapeutic outcomes.

Recent advancements in pharmacological research have introduced promising therapeutic strategies such as dual incretin receptor agonists, gene therapy, stem cell therapy, and nanotechnology-based drug delivery systems. Continued research and innovation will be essential to develop more

effective and safer treatments for diabetes mellitus in the future.

REFERENCES:

1. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2023.
2. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 2004.
3. Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med. 1993.
4. Riddle MC. Metformin therapy in type 2 diabetes. Diabetes Care. 2012.
5. Drucker DJ. Incretin-based therapies for diabetes. Cell Metab. 2006.
6. Zinman B. Empagliflozin and cardiovascular outcomes. N Engl J Med. 2015.
7. Wild S. Global prevalence of diabetes. Diabetes Care. 2004.
8. Fowler MJ. Microvascular complications of diabetes. Clin Diabetes. 2008.
9. Nauck MA. Incretin hormones and diabetes. Diabetologia. 2011.
10. Holman RR. Long-term follow-up of intensive glucose control. N Engl J Med. 2008.
11. Ferrannini E. SGLT2 inhibitors in diabetes management. Lancet Diabetes Endocrinol. 2017.
12. Buse JB. GLP-1 receptor agonists in diabetes therapy. Lancet. 2016.
13. DeFronzo RA. Combination therapy in diabetes treatment. Diabetes Care. 2010.
14. Garber AJ. Pharmacologic therapy for type 2 diabetes. Endocr Pract. 2020.
15. Bailey CJ. Metformin: mechanisms of action. Diabetologia. 2017.
16. Nauck MA. DPP-4 inhibitors in diabetes. Lancet. 2007.
17. Ceriello A. Diabetes and oxidative stress. Diabetes Care. 2000.
18. Brownlee M. Biochemistry of diabetes complications. Nature. 2001.
19. Shapiro AM. Stem cell therapy in diabetes. Lancet. 2000.
20. Chatterjee S. Global burden of diabetes. Lancet Diabetes Endocrinol. 2017.